Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A1 | O15245 | 1/20 | 0.47 |
| ▸ | HTR1A | P08908 | 1/20 | 0.47 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.47 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.47 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
| ▸ | DRD1 | P21728 | 1/20 | 0.47 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | HTR2C | P28335 | 1/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 1/20 | 0.47 |
| ▸ | HTR2B | P41595 | 1/20 | 0.47 |
| ▸ | MTOR | P42345 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10565358 | 0.80 | SLC22A1 (0.46) | SLC22A1HTR1AADRA2ACHRM1ADRA2B | |
| SCHEMBL13128180 | 0.80 | SLC22A1 (0.46) | SLC22A1HTR1AADRA2ACHRM1ADRA2B | |
| SCHEMBL1096556 | 0.77 | L3MBTL1 (0.51) | SMN1; SMN2MEN1KMT2AALDH1A1TDP1 | |
| SCHEMBL2083905 | 0.77 | L3MBTL1 (0.51) | SMN1; SMN2MEN1KMT2AALDH1A1TDP1 | |
| SCHEMBL28618300 | 0.76 | ALDH1A1 (0.50) | SMN1; SMN2MEN1KMT2AALDH1A1NPSR1 | |
| SCHEMBL4638980 | 0.76 | POLB (0.41) | SMN1; SMN2MEN1KMT2AALDH1A1TDP1 | |
| SCHEMBL10770265 | 0.74 | ALDH1A1 (0.44) | SLC22A1HTR1AADRA2ACHRM1ADRA2B | |
| SCHEMBL3280624 | 0.74 | ALDH1A1 (0.44) | SLC22A1HTR1AADRA2ACHRM1ADRA2B | |
| SCHEMBL10613416 | 0.73 | SLC22A1 (0.57) | SLC22A1HTR1AADRA2ACHRM1ADRA2B | |
| SCHEMBL11887770 | 0.73 | SLC22A1 (0.57) | SLC22A1HTR1AADRA2ACHRM1ADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110452235-B | Fluorine-containing isoxazole compound and preparation method, pharmaceutical composition and application thereof | 中国科学院上海药物研究所 | 2023-02-17 | — | — | CN | disclosed |
| CN-115504972-A | Isoxazole derivatives, preparation method thereof and application thereof as medicines | 广东药科大学 | 2022-12-23 | — | — | CN | disclosed |
| US-8153624-B2 | Compounds and methods for modulating FXR | ELI LILLY AND COMPANY (US) | 2012-04-10 | — | — | US | disclosed |
| EP-2178851-B1 | COMPOUNDS AND METHODS FOR MODULATING FXR | LILLY CO ELI (US) | 2011-12-28 | — | — | EP | disclosed |
| US-20100152166-A1 | COMPOUNDS AND METHODS FOR MODULATING FXR | ELI LILLY AND COMPANY (US) | 2010-06-17 | — | — | US | disclosed |
| EP-2178851-A1 | COMPOUNDS AND METHODS FOR MODULATING FXR | Eli Lilly & Company (US) | 2010-04-28 | — | — | EP | disclosed |
| WO-2009012125-A1 | COMPOUNDS AND METHODS FOR MODULATING FXR | ELI LILLY AND COMPANY (US) | 2009-01-22 | — | — | WO | disclosed |
| EP-1501808-B1 | TACHYKININ RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2008-07-02 | — | — | EP | disclosed |
| US-7179804-B2 | Tachykinin receptor antagonists | ELI LILLY AND COMPANY (US) | 2007-02-20 | — | — | US | disclosed |
| US-20050239776-A1 | Tachykinin receptor antagonists | ELI LILLY AND COMPANY (US) | 2005-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239776-A1 | Tachykinin receptor antagonists | TACR2, TACR1, PROKR1 | SLC22A1 559/4885HTR1A 277/4885ADRA2A 249/4885 |
| US-20100152166-A1 | COMPOUNDS AND METHODS FOR MODULATING FXR | NR1H4, FXR1, SLC10A1 | SLC22A1 641/4885HTR1A 1890/4885ADRA2A 949/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.